Seeking Novel Therapeutic Approaches for Circadian Rhythm Sleep Disorder (CRSD) and/or Disease-Comorbid Insomnia

This campaign has been commissioned by an international Japanese pharmaceutical company who combat diseases using a combination of ground‑breaking technology and biology, with an extensive track record of academic collaboration. They are seeking novel therapeutic approaches for Circadian Rhythm Sleep Disorder (CRSD) and/or disease-comorbid insomnia.

Approaches of Interest

• Clinical development candidate (any modality including small molecules, antibodies, etc.) 
• Casein Kinase-1 inhibitor which has clear advantage compared to BIIB-118 (Biogen/Pfizer, Phase 1) 
• Clock gene (e.g. Period, Cry, REV-ERB, ROR) targeted programs
• Novel target or mechanism for the treatment of CRSD and/or disease-comorbid insomnia
• All four types of CRSD are within scope (Delayed, Advanced, Irregular, N24)
• Validation through in vivo models (e.g. animal models) is preferred, but in vitro validation is also within scope
• Development of highly predictable or translational preclinical models of CRSD or co‑morbid insomnia are of particular interest

Out of Scope

Conventional targets and approaches, e.g. Orexin, melatonin, benzodiazepine, and related sub-receptors.

Developmental Stages of Interest

Research at basic stage through to phase I of clinical trials is within scope, with preclinical research being of highest interest.

Jurisdictions of Interest

Our client is open to opportunities worldwide.